<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03541954</url>
  </required_header>
  <id_info>
    <org_study_id>RC17_0427</org_study_id>
    <nct_id>NCT03541954</nct_id>
  </id_info>
  <brief_title>Neurophysiological Validation of the Clinical Criteria of Sensitization in Chronic Pelvic and Perineal Pain Population</brief_title>
  <acronym>DOPEC</acronym>
  <official_title>Neurophysiological Validation of the Clinical Criteria of Sensitization in Chronic Pelvic and Perineal Pain Population : a Prospective Controlled Interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess and validate the clinical criteria of sensitization
      (&quot;Convergences PP criteria&quot;) selected by the expert consensus with neurophysiological sensory
      testing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Some patient with chronic pelvic or perineal pain, present complex manifestations, comprising
      pain and dysfunction which does not involved a single organ. The gap between clinical
      symptoms and pathological signs is a constant feature of these pain syndromes. A possible
      explanation for these pain syndromes is central sensitization. This sensitization is defined
      by decrease nociceptive thresholds, a more intense and more prolonged response to nociceptive
      stimulus, and spatial extension of the painful area. It has been defined by international
      expert consensus in 2016 a clinical evaluation tool with 10 criteria for sensitization
      diagnosis: Convergences PP criteria. The aim of this study is to objectivize lower threshold,
      spatial and temporal diffusion of pain in women with chronic pelvic or perineal pain with
      sensitization (Convergences PP criteria &gt; 5) compared to women without sensitization
      (Convergences PP criteria &lt; 5). A sensory testing of lower urinary tract, lower rectal tract,
      vulva and pelvic muscles will be achieved.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2018</start_date>
  <completion_date type="Anticipated">December 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 17, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 types of patients will be included:
30 patients with chronic pelvic or perineal pain with sensitization (Convergences PP criteria &gt; 5)
30 patients with chronic pelvic or perineal pain without sensitization (Convergences PP criteria &lt; 5)</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of pelvic pain threshold</measure>
    <time_frame>1 month after inclusion in the study</time_frame>
    <description>Comparison of pelvic pain threshold obtained by 4 neurophysiological testing, between women with chronic pelvic or perineal pain with sensitization (Convergences PP criteria &gt; 5) and without sensitization (Convergences PP criteria &lt; 5).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of temporal distribution of pain</measure>
    <time_frame>1 month after inclusion in the study</time_frame>
    <description>Identification of temporal distribution of pain in women with chronic pelvic or perineal pain with sensitization (Convergences PP criteria &gt; 5) compared to women without sensitization (Convergences PP criteria &lt; 5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of lower pain perception thresholds</measure>
    <time_frame>1 month after inclusion in the study</time_frame>
    <description>Identification of lower pain perception thresholds in women with chronic pelvic or perineal pain with sensitization (Convergences PP criteria &gt; 5) compared to women without sensitization (Convergences PP criteria &lt; 5) for each of the 4 neurophysiological testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of state anxiety</measure>
    <time_frame>1 month after inclusion in the study</time_frame>
    <description>Comparison of state anxiety between women with chronic pelvic or perineal pain with sensitization (Convergences PP criteria &gt; 5) and without sensitization (Convergences PP criteria &lt; 5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of depression</measure>
    <time_frame>1 month after inclusion in the study</time_frame>
    <description>Comparison of depression between women with chronic pelvic or perineal pain with sensitization (Convergences PP criteria &gt; 5) and without sensitization (Convergences PP criteria &lt; 5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of catastrophizing</measure>
    <time_frame>1 month after inclusion in the study</time_frame>
    <description>Comparison of catastrophizing between women with chronic pelvic or perineal pain with sensitization (Convergences PP criteria &gt; 5) and without sensitization (Convergences PP criteria &lt; 5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of quality of life</measure>
    <time_frame>1 month after inclusion in the study</time_frame>
    <description>Comparison of quality of life between women with chronic pelvic or perineal pain with sensitization (Convergences PP criteria &gt; 5) and without sensitization (Convergences PP criteria &lt; 5).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Pelvic Pain</condition>
  <condition>Chronic Perineal Pain</condition>
  <arm_group>
    <arm_group_label>Patient with pelvic or perineal pain with sensitization</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with chronic pelvic or perineal pain with sensitization (Convergences PP criteria &gt; 5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with pelvic or perineal pain without sensitization</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with chronic pelvic or perineal pain without sensitization (Convergences PP criteria &lt; 5)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sensory testing of lower urinary tract.</intervention_name>
    <description>Non invasive lower urinary tract sensitivity testing: provoked diuresis with sonographic estimates of sensory thresholds.</description>
    <arm_group_label>Patient with pelvic or perineal pain with sensitization</arm_group_label>
    <arm_group_label>Patient with pelvic or perineal pain without sensitization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sensory testing of lower rectal tract</intervention_name>
    <description>Lower digestive tract sensitivity testing: rectal electronic barostat with ascending pressure (phasic distension).</description>
    <arm_group_label>Patient with pelvic or perineal pain with sensitization</arm_group_label>
    <arm_group_label>Patient with pelvic or perineal pain without sensitization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sensory testing of vulva muscles</intervention_name>
    <description>Vulvar sensitivity testing: pressure pain threshold evaluated using vulvagesiometer.</description>
    <arm_group_label>Patient with pelvic or perineal pain with sensitization</arm_group_label>
    <arm_group_label>Patient with pelvic or perineal pain without sensitization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sensory testing of pelvic muscles</intervention_name>
    <description>Myofascial sensitivity testing: piriformis, levator ani and obturator internus muscles pressure pain threshold evaluated using intra-vaginal algometer.</description>
    <arm_group_label>Patient with pelvic or perineal pain with sensitization</arm_group_label>
    <arm_group_label>Patient with pelvic or perineal pain without sensitization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women &gt; 25 years,

          -  Pelvic or perineal pain since &gt; 3 months,

          -  No injury in pelvic imagery or clinical examination that may explain all the pain
             complaint,

          -  Patient who can understand the protocol,

          -  Patient who agreed and signed the informed consent for participation.

        Exclusion Criteria:

          -  Poor understanding of French language,

          -  Pregnancy or lactation,

          -  Severe depression (Beck Depression Inventory-Short form &gt; 16),

          -  Initial pain estimation at 10 on numeric analog scale,

          -  Inadequately cooperating,

          -  Isolated dysmenorrhea,

          -  Deep endometriosis with rectal or bladder lesion,

          -  Genital or bladder infection,

          -  Urogenital tumor history,

          -  Anorectal surgery history a type of digestive resection,

          -  Anal stenosis,

          -  Advanced vaginal prolapse (stage 2 on POP-Q scale),

          -  Post-traumatic stress disorder history,

          -  Deprived of liberty (trusteeship, guardianship).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stephane PLOTEAU, Doctor</last_name>
    <phone>+33 2 40 08 76 84</phone>
    <email>stephane.ploteau@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claire CARDAILLAC, Medical Student</last_name>
    <email>cardaillac.c@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nantes university Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>St√©phane PLOTEAU, Doctor</last_name>
      <phone>+33 2 40 08 76 84</phone>
      <email>stephane.ploteau@chu-nantes.fr</email>
    </contact>
    <contact_backup>
      <last_name>claire cardaillac</last_name>
      <email>cardaillac.c@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Groupe Confluent</name>
      <address>
        <city>Nantes</city>
        <zip>44277</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thibault RIANT, Doctor</last_name>
      <email>thibault.riant@groupeconfluent.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sensitization</keyword>
  <keyword>pain thresholds</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pelvic Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

